Creative Medical Technology Holdings Inc 's Revenue per employee fell on a trailing twelve month basis to $ 750, but the productivity of Creative Medical Technology Holdings Inc 's employees remained above the company average.
Within the Healthcare sector Creative Medical Technology Holdings Inc achieved the highest revenue per employee. While revenue per employee remained unchanged compared to the previous quarter at no. .Creative Medical Technology Holdings Inc has 4 employees.

What is Sales per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Revenue per Employee▼

None ▼

Revenue per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CELZ Revenue per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Revenue Change	-	-	0 %	-	-
Sales per Employee (TTM) $	750	750	1,500	1,500	1,500
CELZ's Total Ranking	#	#	#	#	#
Seq. Revenue Change	-	-	-	-	-

CELZ Company Profile >> Back to CELZ Efficiency Comparisons >> Compare CELZ Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	#
Healthcare Sector	#
Overall Market	#

Revenue per Employee Statistics
High	Average	Low
$ 56,875	$ 38,527	$ 17,900
(Sep 30 2019)		(Sep 30 2018)

Financial Statements
Creative Medical Technology Holdings Inc 's Revenue MRQ	$ 0 Millions	Visit CELZ's Income Statement
Creative Medical Technology Holdings Inc 's Revenues TTM	$ 0 Millions	Visit CELZ's aggregate revenue growth
What are CELZ's Sales?		Visit CELZ's Sales by Segment

News about Creative Medical Technology Holdings Inc Revenue per employee

Revolutionizing Regenerative Medicine: Medical Technology Holdings Leads the Charge in IVF and Chronic Pain Treatments

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is making waves in the health and wellness sector with its innovative approaches to reproductive health and pain management. The company is garnering attention not only for its pioneering OvaStem program, which enhances access to in vitro fertilization (IVF), but also for its significant advancements in treating chronic lower back pain through its groundbreaking CELZ-201 therapy. With a focus on safety and efficacy, Creative Medical Technology is positioning itself as a frontrunner in the burgeoning field of regenerative medicine. Expanding IVF Access: A Presidential InitiativeAs part of a broader initiative to improve access to reproductive health services, the presidential administration has heralded a new era for IVF accessibility. This timely focus aligns closely with Creative Medical Technology s efforts through its OvaStem program, which is designed to enhance the quality of oocytes (eggs) harvested from women undergoing fertility treatments. OvaStem aims to provide a more efficient and effective approach to IVF, ultimately leading to improved outcomes for patients.

Innovative Regenerative Approach Medical Technologys Breakthrough in Chronic Lower Back Pain Treatment

In an exciting advancement for the field of regenerative medicine, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has announced a significant milestone in its ADAPT clinical trial. As of November 13, 2024, the independent Data Safety Monitoring Board (DSMB) has successfully completed an interim safety review, affirming the safety and potential efficacy of CELZ-201, a groundbreaking therapeutic product derived from perinatal tissues. This innovative approach aims to address the widespread and debilitating issue of chronic lower back pain associated with degenerative disc disease.Chronic lower back pain is a prevalent condition that affects millions of individuals globally, often leading to a substantial decline in quality of life and increased healthcare costs. Traditional surgical interventions and pain management strategies can sometimes fall short, prompting researchers and medical professionals to seek out novel therapies that promote healing and regeneration.

Other Ratios
Creative Medical Technology Holdings Inc 's Income per Employee
Employees in Biotechnology & Pharmaceuticals
Biotechnology & Pharmaceuticals Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
CELZ's Revenue per Employee versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for CELZ's Competitors
Revenue per Employee for CELZ's Suppliers
Revenue per Employee for CELZ's Customers

You may also want to know
CELZ's Sales Growth Rates	CELZ's Pe Price to earnings ratio	CELZ's Receivables Turnover Ratio	CELZ's Stock Quote
CELZ's Net Income Growth Rates	CELZ's Ps Price to Sales ratio	CELZ's Sales per Employee	CELZ's Asset Turnover Ratio
CELZ's Net Margin	CELZ's Pb Price to Book ratio	CELZ's Financial Strength Ratios	CELZ's Dividend Payout Ratio

Date modified: 2026-08-14T09:13:33+00:00

Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector	Revenue per Employee	Revenue 12 months ending Jun 30 2026	Number of Employees Jun 30 2026
Sera Prognostics Inc	972.22	$ 0.070 Million	72
Cardio Diagnostics Holdings Inc	850.00	$ 0.014 Million	17
Quoin Pharmaceuticals Ltd	837.83	$ 0.005 Million	6

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.